Redcliffe Labs

Positions itself as expanding access to affordable, high-quality diagnostic testing, especially in underserved geographies.

Offers a broad catalogue of routine pathology and specialised tests including genetics/DNA testing.

Combines home sample collection, a network of owned labs, and collection centres/franchise points so patients can choose how they get tested.

Markets on-demand 1-hour home sample collection and same-day report delivery as a speed differentiator.

Direct-to-consumer patients booking home sample collection or visiting collection centres for routine pathology, wellness and genetic tests.

Patients whose testing choices are shaped by physician involvement: Redcliffe markets its health checkup packages as doctor-curated and doctor-trusted, using doctor endorsement as an acquisition signal. (No public source found substantiates a formal clinics/hospitals referral-partner B2B2C arrangement, so the claim is narrowed to what this citation actually supports.)

Underserved smaller-city and semi-urban populations targeted for expansion of affordable diagnostics access.

Healthcare professionals, phlebotomists, lab technicians and entrepreneurial partners who open Redcliffe-branded collection centres under its franchise program.

Fleet of phlebotomists performing at-home sample collection across cities.

Network of owned, NABL-accredited diagnostic labs processing tests.

Third-party franchise-operated collection centres extending reach into new cities under the Redcliffe brand.

Redcliffe offers a dedicated mobile app (downloadable via QR code) for booking tests, managing accounts and accessing exclusive offers, alongside web-based online booking.

Physical network of owned labs plus franchise collection centres and pickup points across India.

In-house/franchise phlebotomist workforce enabling home sample collection at scale.

Integrated CRM and technology stack supporting franchise operations and logistics for sample management.

Danish development finance institution; led the $42 Mn Series C round with a $20 Mn commitment.

Existing investor that led the $61 Mn Series B and contributed $15 Mn to the Series C.

World Bank Group's private-sector arm; disclosed a proposed equity investment of up to $30 million via compulsorily convertible debentures, pending approval as of April 2026.

Bengaluru-based radiology and pathology provider acquired by Redcliffe Labs for up to Rs 60 crore ($7 Mn); Redcliffe's second acquisition of 2024, part of a roll-up strategy targeting financially strong labs per founder Dheeraj Jain. The source confirms Celara is Bengaluru-based but does not state a South-India-expansion rationale for this specific deal.

The large majority of operating revenue comes from pathology/lab test fees.

Smaller revenue line from sale of health/diagnostics-related products.

Redcliffe runs a franchise program for collection centres, but public financial disclosures don't break out franchise-specific revenue separately from the pathology-testing and product-sales lines above. The cited page markets franchisee (partner) economics -- not Redcliffe's own fee structure -- so this is filed as a likely but unconfirmed revenue channel rather than a verified one.